var data={"title":"Ciclesonide (nasal): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ciclesonide (nasal): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/387891?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ciclesonide-nasal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ciclesonide (nasal): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=ciclesonide-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ciclesonide (nasal): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002704\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Omnaris;</li>\n      <li>Zetonna</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002705\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Drymira;</li>\n      <li>Omnaris;</li>\n      <li>Omnaris HFA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8007837\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Nasal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002756\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Perennial allergic rhinitis, seasonal allergic rhinitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omnaris: Two sprays (50 mcg/spray) per nostril once daily; maximum: 200 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zetonna: One spray (37 mcg/spray) per nostril once daily; maximum: 74 mcg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002755\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ciclesonide-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ciclesonide (nasal): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perennial allergic rhinitis:</b> Children &ge;12 years and Adolescents: Refer to adult dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Seasonal allergic rhinitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Omnaris: Children &ge;6 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zetonna: Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002757\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682646\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682647\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002800\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zetonna: 37 mcg/actuation (6.1 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnaris: 50 mcg/actuation (12.5 g) [contains edetate sodium (tetrasodium)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002706\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005931\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;\">Omnaris 12.5 g bottles contain 120 actuations. </p>\n    <p style=\"text-indent:0em;\">Zetonna 6.1 g canisters contain 60 actuations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002782\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Intranasal</b> Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Avoid spraying directly onto the nasal septum or into eyes. Discard after the &quot;discard by&quot; date or after labeled number of doses has been used, even if bottle is not completely empty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omnaris: Shake bottle gently before using. Prime pump prior to first use (press 8 times until fine mist appears) or if spray has not been used in 4 consecutive days (press 1 time or until a fine mist appears). Nasal applicator may be removed and rinsed with warm water to clean.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zetonna: Use nasal canister with supplied nasal actuator only. Prime pump prior to first use (press 3 times until fine mist appears) or if spray has not been used in 10 consecutive days (press 3 times or until a fine mist appears). If canister and actuator become separated, spray 1 test spray in air before using. Clean outside of nose piece with a clean, dry tissue or cloth weekly; do not wash or put in water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002708\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Seasonal and perennial allergic rhinitis: </b>Management of seasonal and perennial allergic rhinitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475334\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute bacterial rhinosinusitis, adjunct to antibiotics (empiric treatment):; Chronic rhinosinusitis:</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002721\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (&ge;2%), strain (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (2% to 7%), nasal discomfort (3% to 6%), pharyngolaryngeal pain (&ge;3%), bronchitis (&ge;2%), cough (&ge;2%; may be dose-responsive), nasal septum disorder (&ge;2%; may be dose-responsive), oropharyngeal pain (&ge;2%), sinusitis (&ge;2%), streptococcal pharyngitis (&ge;2%), viral upper respiratory tract infection (&ge;2%), upper respiratory infection (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema (with angioedema of the lips, angioedema of the oropharynx, and angioedema of the tongue), dizziness, dysgeusia, dyspepsia, leukocytosis, nasal candidiasis, nasal congestion, nasal mucosa ulcer, pharyngeal candidiasis, rhinorrhea, throat irritation, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002709\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ciclesonide or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Active or quiescent tuberculosis infections of the respiratory tract.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002710\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: When used at excessive doses, may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should be used with caution, if at all, in patients with ocular herpes simplex, latent tuberculosis, and/or TB reactivity, or in patients with untreated fungal, viral, or bacterial infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local nasal effects: Nasal septal perforation, nasal ulceration, epistaxis, and localized <i>Candida albicans</i> infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with intranasal corticosteroid use; use with caution in patients with a history of increased intraocular pressure, cataracts and/or glaucoma. Consider routine eye exams in chronic users or in patients who report visual changes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002734\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002735\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9043&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Nasal) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8043197\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8043198\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor. Intranasal corticosteroids may be used in the treatment of rhinitis during pregnancy; the lowest effective dose should be used (NAEPP, 2005; Wallace, 2008). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13766079\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of ciclesonide are absorbed following nasal inhalation to produce detectable amounts in breast milk; however, oral absorption is limited (&lt;1%). The use of inhaled corticosteroids is not considered a contraindication to breast-feeding (NAEPP, 2005). The manufacturer recommends caution be used if administered to a nursing woman. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002743\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 24-48 hours; further improvement observed over 1-2 weeks in seasonal allergic rhinitis or 5 weeks in perennial allergic rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Minimal systemic absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Ciclesonide hydrolyzed to active metabolite, des-ciclesonide via esterases in nasal mucosa and lungs; further metabolism via hepatic CYP3A4 and 2D6</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: &lt;1%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002803\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Zetonna Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37 mcg/ACT (6.1 g): $308.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Omnaris Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/ACT (12.5 g): $308.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390226\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ciclex (BD);</li>\n      <li>Ciclomate NS (LK);</li>\n      <li>Cicloson (BD);</li>\n      <li>Omnaris (AE, AR, AU, BR, CR, DO, GT, HK, HN, KR, LB, MY, NI, PA, PH, QA, SG, SV, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nave R, Wingertzahn MA, Brookman S, et al, &ldquo;Safety, Tolerability, and Exposure of Ciclesonide Nasal Spray in Healthy and Asymptomatic Subjects with Seasonal Allergic Rhinitis,&rdquo; <i>J Clin Pharmacol</i>, 2006, 46 (4):461-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/16554455/pubmed\" target=\"_blank\" id=\"16554455\">16554455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Omnaris (ciclesonide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2 suppl):S1-S39. doi: 10.1177/0194599815572097.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/25832968/pubmed\" target=\"_blank\" id=\"25832968\">25832968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI, et al, &ldquo;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&rdquo; <i>J Allergy Clin Immunol</i>, 2008, 122(2 Suppl):1-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9043 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8002704\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8002705\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8007837\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8002756\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8002755\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8002757\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682646\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682647\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8002800\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8002706\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005931\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8002782\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8002708\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475334\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8002721\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8002709\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8002710\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8002734\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8002735\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8043197\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8043198\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13766079\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8002743\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8002803\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390226\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9043|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ciclesonide-nasal-patient-drug-information\" class=\"drug drug_patient\">Ciclesonide (nasal): Patient drug information \t</a></li><li><a href=\"topic.htm?path=ciclesonide-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">Ciclesonide (nasal): Pediatric drug information</a></li></ul></div></div>","javascript":null}